Actively Recruiting
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
Led by Liu Huang · Updated on 2025-05-20
42
Participants Needed
1
Research Sites
192 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glumetinib combined withFruquintinib in the treatment of MET amplification or protein overexpression in third-line unresectable metastatic colorectal cancer: evaluation of efficacy and safety
CONDITIONS
Official Title
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years or older
- Patients who fully understand the study and voluntarily sign informed consent
- Patients with unresectable metastatic colorectal cancer confirmed microsatellite stable
- Patients with MET amplification or protein overexpression confirmed by specific tests
- Patients whose disease has progressed after two prior standard anti-tumor treatments
- Patients with at least one measurable tumor lesion according to RECIST1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Expected survival time of 3 months or more
- Adequate blood counts: ANC ≥1.5 x 10^9/L, platelets ≥75 x 10^9/L, hemoglobin ≥80 g/L, WBC ≥3.0 x 10^9/L
- Adequate liver and kidney function within specified limits
- Coagulation tests (APTT, INR, PT) less than or equal to 1.5 times normal upper limit
- Women of childbearing age must have a negative pregnancy test within 7 days before enrollment and agree to contraception during and 6 months after treatment
- Male participants must agree to use contraception during and 6 months after the study
You will not qualify if you...
- Previous treatment with MET inhibitors
- Patients with metastatic colorectal cancer that is MSI-H or dMMR
- Patients with BRAF gene mutation who have not received BRAF or MEK inhibitors
- Patients with severe active bleeding, active peptic ulcers, unhealed gastrointestinal perforations, or fistulas
- Known hypersensitivity to study drugs or their components
- Severe uncontrolled infections or other serious uncontrolled diseases including moderate or severe kidney injury
- Active hepatitis B or C infection with viral loads above specified levels
- Human immunodeficiency virus (HIV) infection
- Current or past other malignant tumors except certain controlled cancers
- Pregnant or breastfeeding women or those unwilling to use contraception
- Patients with other malignant tumors requiring treatment
- Any condition that the investigator judges makes the patient unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
X
Xianglin Yuan, PhD,MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here